Tel:+86-027-59403931 Ext 8009 
Email: wwqin@oryzogen.com
Contact Us
Inquiry Now 
Tags
ListA total of 6 articles were found
-
Healthgen Obtains CMMM Level 3 Certification
On August 11, 2026,Wuhan Healthgen Biotechnology CO.,LTD. officially obtained the "Certification of Compliance with the Intelligent Manufacturing Capability Maturity Model" (Certificate Number: CMMM-027-2761-2026-2162), with an assessme...
Category: NEWS -
ISSCR 2026-Healthgen Biotech showcases rice-derived rHSA
MONTREAL, July 8–11, 2026 – The International Society for Stem Cell Research (ISSCR), the world’s leading cross-disciplinary authority spanning over 80 countries, dedicated to advancing the translation of basic stem cell research into c...
Category: NEWS -
Healthgen Biotech to attend KOREA PHARM & BIO 2026
Healthgen Biotech will participate in KOREA PHARM & BIO 2026, which takes place in Gyeonggi-do from 31th March to 3rd April. Exhibition: KOREA PHARM & BIO 2026 Location: KINTEX 2 (Korea International E...
Category: NEWS -
Healthgen Announces Listing on October 28, 2025
On the morning of October 28, 2025, Wuhan Healthgen Biotechnology Corp. (Stock Name: Healthgen Biotech; Stock Code: 688765) was officially listed on the Shanghai Stock Exchange, marking its status as the first listed company specializin...
Category: NEWS -
Gut commentary highlighting the significant clinical implications of Olbumin®
The official journal of the British Society of Gastroenterology, Gut (Impact Factor 25.8), recently published an in-depth commentary by Professor Rajiv Jalan of University College London and Professor Paolo Caraceni of the University of...
Category: NEWS -
Olbumin® receives approval to initiate Phase III Clinical Trials in US
Recently, Healthgen’s proprietary, first-in-class drug, Recombinant Human Albumin Injection (Oryza Sativa), successfully has successfully completed a Type C meeting with the U.S. FDA. During the meeting, Healthg...
Category: NEWS